We're Here for You!
The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure.
Ready to nurture your resilience? Follow the IMF's Myeloma Action Month (MAM) March calendar that features "31 Days of Resilience.” The focus is on small actions you can do each day of the week. Some examples include taking a walk, catching up with a family member, or watching the sunrise. And, if you are not up for the daily action, perhaps you will choose to share a fact about myeloma on your social media channels. The ways to get involved this March are easy and varied, so take a look at the MAM website to get your creative juices flowing!
Calling it "a win for patients," the International Myeloma Foundation (IMF) welcomed FDA approval on March 26 of Abecma (idecabtagene vicleucel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy.
Dr. Brian G.M Durie discusses Abecma, the new FDA-approved anti-BCMA CAR T cell-therapy, which is only available at designated centers in the U.S. He also talks about cautions to take during vaccine rollouts.
According to a press release from Sanofi, "The U.S. Food and Drug Administration (FDA) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd), for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received one to three prior lines of therapy."
On March 29, 2021, according to a press release from Karyopharm Therapeutics, "the European Commission (EC) has granted conditional marketing authorization for NEXPOVIO (selinexor), the Company's first-in-class, oral Selective Inhibitor of Nuclear Export (SINE) medicine, in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy." Click to learn more.
Need to stay informed about the news that impacts myeloma patients, but don’t have time to read everything out there? Then be sure to follow Dr. Brian Durie’s Week in Review blog. The leading myeloma expert and IMF Chairman of the Board drills down on a wide range of topics – from the latest myeloma research results to the environmental issues that offer insight into prevention. He sifts through the data to deliver the bottom line.
Last year marks the International Myeloma Foundation's (IMF) 30th anniversary, celebrating 30 years of scientific achievement with myeloma patient care at the heart of it all. What started in a garage with a borrowed typewriter is now the largest organization focused specifically on multiple myeloma. The IMF continues to push the needle forward toward a cure for myeloma with cure-focused trials and over 40 active research projects around the world. As IMF President and Founder Susie Durie says, "We are this close to the cure. I can see it on the horizon."
The IMF stands together with the Black community in calling for justice and racial equality. We believe unconditionally, that Black lives matter.
The support of loved ones allows us to continue to fund efforts to search for a cure. Check out how Fundraisers are helping in the fight against myeloma.
